Current treatment of basilar artery occlusion

Ann N Y Acad Sci. 2012 Sep:1268:35-44. doi: 10.1111/j.1749-6632.2012.06687.x.

Abstract

Basilar artery occlusion (BAO) is associated with high mortality (85-95%) if recanalization does not occur. Evidence of the efficacy of different therapy protocols of intravenous thrombolysis (IVT) or intraarterial thrombolysis (IAT) and/or mechanical endovascular treatment is based on retrospective or prospective patient cohorts, since randomized controlled trials (RCTs) do not exist. Roughly a third of BAO patients reach independent outcome following thrombolysis. From those in whom recanalization occurs, about half will reach independence. In noninvasive and endovascular protocols, recanalization of BAO is reached in 60-85% of the patients. While invasive endovascular approaches afford greater recanalization rates, they have not been proven superior to IVT in terms of functional outcome. Meaningful survival after BAO requires rapid access to thrombolysis. "Bridging" protocols have been introduced where rescue therapies such as endovascular thrombolysis and on-demand mechanical thrombectomy or angioplasty are used. Multimodal imaging techniques should be used to choose the best therapeutic option individually.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Algorithms
  • Cerebral Revascularization* / methods
  • Cohort Studies
  • Contraindications
  • Diagnosis, Differential
  • Endovascular Procedures
  • Fibrinolytic Agents / therapeutic use
  • Hospital Units
  • Humans
  • Neuroimaging / methods
  • Patient Selection
  • Phenotype
  • Prognosis
  • Thrombectomy
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Vertebrobasilar Insufficiency / classification
  • Vertebrobasilar Insufficiency / diagnosis
  • Vertebrobasilar Insufficiency / drug therapy*
  • Vertebrobasilar Insufficiency / surgery

Substances

  • Fibrinolytic Agents